This is a Ph3 trial mate, from start to finish. The interim results give us opportunity on meeting endpoints in data to go to Regulators for priority review & drug approval on interim data. The trial will continue, but that could mean Orphan Drug Approval prior to completion. Not forgetting UK also (read back through ANNs). Very different to Ph2..
None of us are in reverse gear with age, but it is how you set your mind to it for sure & resilience. Take Care BTB, & it has been a tough couple of years & still is, but for clinical trials things have changed a lot.
Ann: FDA IND Approval for Phase 3 Study of DMX-200 in FSGS, page-50
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $186.8M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.5¢ | 33.5¢ | $1.194M | 3.480M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 181739 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 395705 | 4 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
34.0¢ |
Change
-0.005 ( 1.45 %) |
||||
| Open | High | Low | Volume | ||
| 35.0¢ | 35.5¢ | 33.5¢ | 1411237 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| DXB (ASX) Chart |